{"id":3308,"date":"2026-04-22T21:02:19","date_gmt":"2026-04-22T21:02:19","guid":{"rendered":"https:\/\/digitalmarkettrends.com\/index.php\/2026\/04\/22\/why-are-cannabis-stocks-surging-today\/"},"modified":"2026-04-22T21:02:19","modified_gmt":"2026-04-22T21:02:19","slug":"why-are-cannabis-stocks-surging-today","status":"publish","type":"post","link":"https:\/\/digitalmarkettrends.com\/index.php\/2026\/04\/22\/why-are-cannabis-stocks-surging-today\/","title":{"rendered":"Why are cannabis stocks surging today?"},"content":{"rendered":"
<\/div>\n

Shares of major cannabis companies rallied sharply on Wednesday after reports suggested the Trump Administration could soon move to reclassify marijuana, a long-awaited step that investors believe could ease regulatory pressures on the sector.<\/p>\n

The gains were led by Curaleaf Holdings, which surged more than 27%. <\/p>\n

Tilray rose 11%, while Canopy Growth climbed over 18%. Aurora Cannabis also advanced, gaining 7.6%.<\/p>\n

The rally extended beyond producers, with Innovative Industrial Properties, a real estate investment trust focused on the industry, rising 5.6%. <\/p>\n

Cannabis-focused exchange-traded funds also saw strong inflows, reflecting broader investor optimism.<\/p>\n

Why are reclassification hopes driving positive sentiment?<\/h2>\n

According to an Axios report, the administration is expected to shift cannabis from Schedule I to Schedule III under federal drug laws. <\/p>\n

Under the US Controlled Substances Act, marijuana is currently classified as a Schedule I drug\u2014placing it alongside substances like heroin\u2014indicating a high risk of abuse and no recognised medical use.<\/p>\n

In 2025, the Biden administration directed the Department of Health and Human Services to reassess this classification. <\/p>\n

The agency subsequently recommended reclassifying marijuana as a Schedule III substance, a category that includes drugs with a lower risk of dependence, such as certain steroids.<\/p>\n

The move would place marijuana in a category alongside medications with accepted medical uses, rather than alongside substances deemed to have no medical value.<\/p>\n

While the change would not legalise marijuana at the federal level, it is seen as a significant milestone for the industry. <\/p>\n

One of the biggest immediate impacts would be on taxation. <\/p>\n

Businesses dealing in Schedule I substances are currently restricted from deducting many expenses, a burden that has weighed heavily on profitability.<\/p>\n

A reclassification could therefore improve financial conditions for operators, even without broader legalisation.<\/p>\n

Regulatory path remains complex<\/h2>\n

Despite the market enthusiasm, analysts caution that the policy shift would not resolve all regulatory challenges. <\/p>\n

Cannabis would remain subject to a patchwork of state-level laws, and federal legalisation would still be required to fully normalise the industry.<\/p>\n

The process of changing marijuana\u2019s classification has been lengthy. <\/p>\n

The US Department of Justice first proposed revisiting its status in 2024, with the Drug Enforcement Administration continuing its review into 2025.<\/p>\n

President Donald Trump had earlier indicated he was weighing policy options before issuing a directive to accelerate the process. <\/p>\n

However, he clarified at the time that any reclassification would not equate to endorsing recreational use.<\/p>\n

Recent policy signals support rally<\/h2>\n

The latest developments follow a series of regulatory signals that have buoyed the sector. <\/p>\n

Earlier this month, the Food and Drug Administration moved to relax enforcement around certain cannabidiol products.<\/p>\n

FDA Commissioner Marty Makary said the agency would not enforce some provisions related to hemp-derived oral products solely due to their CBD content, providing a modest boost to industry confidence.<\/p>\n

Additionally, broader discussions around easing restrictions on emerging therapies, including psychedelics and peptides, have reinforced expectations of a more flexible regulatory stance.<\/p>\n

Market reaction reflects pent-up optimism<\/h2>\n

Cannabis stocks have experienced volatility in recent years, with previous policy announcements often failing to sustain rallies. <\/p>\n

However, Wednesday\u2019s surge suggests investors are increasingly confident that meaningful regulatory change may finally materialise.<\/p>\n

Still, uncertainties remain around the timing and scope of any reclassification. <\/p>\n

Until formal action is taken, the sector is likely to remain sensitive to policy headlines and political developments.<\/p>\n

The post Why are cannabis stocks surging today?<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shares of major cannabis companies rallied sharply on Wednesday after reports suggested the Trump Administration could soon move to reclassify marijuana, a long-awaited step that investors believe could ease regulatory pressures on the sector. The gains were led by Curaleaf Holdings, which surged more than 27%. Tilray rose 11%, while Canopy Growth climbed over 18%. […]<\/p>\n","protected":false},"author":1,"featured_media":3309,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/posts\/3308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/comments?post=3308"}],"version-history":[{"count":0,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/posts\/3308\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/media\/3309"}],"wp:attachment":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/media?parent=3308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/categories?post=3308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/tags?post=3308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}